| Literature DB >> 29058407 |
Marhiah C Montoya1, Louis DiDone2, Richard F Heier3, Marvin J Meyers3,4, Damian J Krysan2,5.
Abstract
New classes of antifungal drugs are an urgent unmet clinical need. One approach to the challenge of developing new antifungal drugs is to optimize the antifungal properties of currently used drugs with favorable pharmacologic properties, so-called drug or scaffold repurposing. New therapies for cryptococcal meningitis are particularly important given its worldwide burden of disease and limited therapeutic options. We report the first systematic structure-activity study of the anticryptococcal properties of the phenothiazines. We also show that the antifungal activity of the phenothiazine scaffold correlates well with its calmodulin antagonism properties and, thereby, provides the first insights into the mechanism of its antifungal properties. Guided by this mechanism, we have generated improved trifluoperazine derivatives with increased anticryptococcal activity and, importantly, reduced affinity for receptors that modulate undesired neurological effects. Taken together, these data suggest that phenothiazines represent a potentially useful scaffold for further optimization in the search for new antifungal drugs.Entities:
Keywords: Candida; Cryptococcus neoformans; antifungal; phenothiazine; repurposing
Mesh:
Substances:
Year: 2017 PMID: 29058407 PMCID: PMC8994671 DOI: 10.1021/acsinfecdis.7b00157
Source DB: PubMed Journal: ACS Infect Dis ISSN: 2373-8227 Impact factor: 5.084